Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a fixed-dose combination inhaler containing three active pharmaceutical ingredients: - Tiotropium, a long-acting muscarinic antagonist (LAMA) that works by inhibiting acetylcholine at muscarinic receptors in the airways, leading to bronchodilation and improved airflow[4][5]. - Formoterol, a long-acting beta2-adrenergic receptor agonist (LABA) that stimulates beta2 receptors on bronchial smooth muscle, resulting in relaxation of airway muscles and bronchodilation[3][5]. - Beclometasone, an inhaled corticosteroid (ICS) that reduces inflammation in the airways by modulating immune cell activity and decreasing the release of inflammatory mediators. The combination is intended for maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It may also be considered for asthma management when symptoms are not adequately controlled with other therapies. The triple therapy targets both bronchoconstriction and airway inflammation to improve lung function and reduce exacerbations[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tiotropium + formoterol + beclometasone.